GAO reviewed U.S. participation with developing countries and international organizations in programs to combat malaria and in efforts to develop effective vaccines and drugs to: (1) obtain an overview of the U.S. investment in combating malaria; and (2) examine current program activities in light of existing policies, strategies, and the prevalence of malaria.
Recommendations for Executive Action
|U.S. Agency for International Development||The Administrator, AID, should direct a reexamination of the existing anti-malaria program guidelines by a panel of experts representing AID, other U.S. agencies, such as the Centers for Disease Control, the international health community, and other appropriate sources to consider the increased prevalence of the disease, new approaches to health service delivery, the particular concerns of the regional bureaus, and the extent to which the agency should support such activities.|
|U.S. Agency for International Development||The Administrator, AID, should alert program managers to situations where assistance would be considered appropriate, what the assistance should accomplish, the circumstances where anti-malaria activities can be incorporated with primary health care programs, and where anti-malaria activities stand in relation to other development opportunities and priorities.|
|U.S. Agency for International Development||The Administrator, AID, should direct that: (1) project designs fully address the inherent constraints to successful anti-malaria activities and also realistically assess the external constraints to long-term effectiveness; and (2) review and approval processes ensure that the constraints do not preclude continued progress.|